Literature DB >> 7845572

Marchiafava-Bignami disease: use of contrast media in CT and MRI.

D Caparros-Lefebvre1, J P Pruvo, E Josien, B Pertuzon, J Clarisse, H Petit.   

Abstract

We report two cases of Marchiafava-Bignami disease studied by CT and MRI. Both patients displayed persistent confusion and a disconnection syndrome but had a favourable outcome. In both cases, CT with intravenous contrast medium revealed enhancement of the corpus callosum in the early stage. MRI showed gadolinium uptake in both the genu and splenium of the corpus callosum in one case, 8 days after the onset. Three weeks after admission, cystic lesions appeared in the corpus callosum on MRI T1-weighted sagittal images in both cases. Contrast medium uptake may be useful in the diagnosis of Marchiafava-Bignami disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7845572     DOI: 10.1007/bf00593509

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  12 in total

1.  Central demyelination of the corpus callosum (Marchiafava-Bignami disease) with report of a second case in Great Britain.

Authors:  R IRONSIDE; F D BOSANQUET; W H McMENEMEY
Journal:  Brain       Date:  1961-06       Impact factor: 13.501

2.  Computerized tomography and MRI in Marchiafava-Bignami disease.

Authors:  S Bracard; D Claude; H Vespignani; M Almeras; M Carsin; H Lambert; L Picard
Journal:  J Neuroradiol       Date:  1986       Impact factor: 3.447

3.  Computerized tomography and nuclear magnetic resonance imaging in Marchiafava-Bignami disease.

Authors:  J M Mayer; P de Liège; J M Netter; F Danzé; D Reizine
Journal:  J Neuroradiol       Date:  1987       Impact factor: 3.447

4.  Marchiafava-Bignami disease.

Authors:  A H Koeppen; K D Barron
Journal:  Neurology       Date:  1978-03       Impact factor: 9.910

5.  [Marchiafava-Bignami disease: anatomoclinical study of 2 cases].

Authors:  P Castaigne; A Buge; J Cambier; R Escourolle; G Rancurel
Journal:  Rev Neurol (Paris)       Date:  1971-09       Impact factor: 2.607

6.  [Interhemispheric disconnection syndrome with diagonistic dyspraxia in the course of Marchiafava-Bignami disease].

Authors:  J Barbizet; J D Degos; A Lejeune; A Leroy
Journal:  Rev Neurol (Paris)       Date:  1978-12       Impact factor: 2.607

7.  Marchiafava-Bignami disease: computed tomographic scan and magnetic resonance imaging.

Authors:  M Kawamura; J Shiota; T Yagishita; K Hirayama
Journal:  Ann Neurol       Date:  1985-07       Impact factor: 10.422

8.  MR imaging of the corpus callosum: normal and pathologic findings and correlation with CT.

Authors:  S J Reinarz; C E Coffman; W R Smoker; J C Godersky
Journal:  AJR Am J Roentgenol       Date:  1988-10       Impact factor: 3.959

9.  [X-ray scanning in Marchiafava-Bignami disease].

Authors:  C Bourrat; M Tommasi; M Bochu; N Kopp; S Malsch
Journal:  Rev Neurol (Paris)       Date:  1984       Impact factor: 2.607

10.  Large focal tumor-like demyelinating lesions of the brain: intermediate entity between multiple sclerosis and acute disseminated encephalomyelitis? A study of 31 patients.

Authors:  J J Kepes
Journal:  Ann Neurol       Date:  1993-01       Impact factor: 10.422

View more
  4 in total

1.  Acute Marchiafava-Bignami disease: MR findings in two patients.

Authors:  Andres Arbelaez; Adriana Pajon; Mauricio Castillo
Journal:  AJNR Am J Neuroradiol       Date:  2003 Nov-Dec       Impact factor: 3.825

Review 2.  Clinicoradiologic subtypes of Marchiafava-Bignami disease.

Authors:  Alexander Heinrich; Uwe Runge; Alexander V Khaw
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

3.  Partial interhemispheric disconnection syndrome (P-IHDS) secondary to Marchiafava-Bignami disease type B (MBD-B).

Authors:  Carlo Canepa; Lorena Arias
Journal:  BMJ Case Rep       Date:  2016-11-23

4.  Transient splenium lesions in presurgical epilepsy patients: incidence and pathogenesis.

Authors:  M Nelles; C G Bien; M Kurthen; M von Falkenhausen; H Urbach
Journal:  Neuroradiology       Date:  2006-05-04       Impact factor: 2.804

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.